| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID5123: Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma |
|
Medicine details |
|
| Medicine name | zolbetuximab (Vyloy®) |
| Formulation | 100 mg powder for concentrate for solution for infusion |
| Reference number | 5207 |
| Indication | Treatment for gastric or gastro-oesophageal junction cancer (HER2-negative, CLDN 18.2 positive, unresectable advanced, untreated) with chemotherapy |
| Company | Astellas Pharma Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/02/2025 |
| NICE guidance | |